Targeting the Expanded TCF4/Fuchs' Endothelial Corneal Dystrophy CUG Repeat with Morpholino Peptide Conjugates
Jiaxin Hu1, Xiulong Shen2, Mahboubeh Kheirabadi2
1Department of Pharmacology and Biochemistry, UT Southwestern Medical Center, 6001 Forest Park Road, Dallas, Texas 75390, United States.
ACS Omega
|November 29, 2023
Summary
New therapies for Fuchs
Area of Science:
- Ophthalmology
- Molecular Biology
- Drug Development
Background:
- Fuchs' corneal endothelial dystrophy (FECD) is a leading cause of vision loss, with corneal transplantation as the primary treatment.
- Current surgical treatments for FECD have limitations, highlighting the need for alternative pharmacological interventions.
- FECD pathogenesis involves an expanded CUG repeat in the TCF4 gene, leading to splicing defects.
Purpose of the Study:
- To evaluate the efficacy of morpholino oligomers conjugated to cell-penetrating peptides as a potential therapeutic strategy for FECD.
- To determine if these conjugates can enter corneal endothelial cells and reduce disease-specific RNA foci.
Main Methods:
- Synthesis of anti-CUG morpholinos conjugated to cyclic cell-penetrating peptides.
- In vitro assessment of conjugate uptake by corneal endothelial cells.
- Analysis of CUG RNA foci in treated cells to confirm therapeutic effect.
Main Results:
- Morpholino-peptide conjugates successfully entered corneal endothelial cells.
- The conjugates effectively blocked the disease-associated CUG RNA foci.
- Demonstrated the potential of this approach for FECD treatment.
Conclusions:
- Morpholino peptide conjugates represent a promising strategy for developing novel anti-CUG therapies for FECD.
- This approach offers a potential pharmacological alternative or adjunct to corneal transplantation.
- Further development of these conjugates could lead to improved treatments for FECD patients.
